Towards the Clinical Management of Cardiac Involvement in Systemic Inflammatory Conditions—a Central Role for CMR

Article (PDF Available)inCurrent Cardiovascular Imaging Reports 11(5):11 · May 2018with 170 Reads 
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
DOI: 10.1007/s12410-018-9451-7
Cite this publication
Abstract
Purpose of ReviewAnti-inflammatory therapies in systemic inflammatory diseases (SID) improve disease-associated disability and may also reduce cardiovascular events. Further optimization of treatment to directly target the inflammation affecting the cardiovascular system represents a potential goal of contemporary treatment. Yet, lack of non-invasive means to detect cardiovascular involvement and to monitor the response to treatment limit such advancements. This is also reflected in the recent 2017 ESC position paper on clinical management of cardiac involvement in SIDs, whose recommendations continue to rely on insensitive, radiation-heavy and invasive diagnostic methods. Absence of evidence and the context of a life-long chronic disease, necessitating ongoing monitoring and serial assessments, puts such recommendations in question. The growing evidence-base for the performance of cardiovascular magnetic resonance (CMR) in patients with SID, and especially of T1 and T2 mapping, offers a viable pathway towards identification of cardiovascular involvement and may potentially guide cardiovascular-specific therapies. Recent FindingsIn this review, we appraise the current evidence for the role of CMR in management of cardiac involvement patients with SID. SummaryWe propose an interdisciplinary framework with a central role for CMR to support the clinical management of cardiac involvement in SID patients.
Advertisement
CARDIAC MAGNETIC RESONANCE (V PUNTMANN AND E NAGEL, SECTION EDITORS)
Towards the Clinical Management of Cardiac Involvement in Systemic
Inflammatory Conditionsa Central Role for CMR
Lea Winau
1
&Eike Nagel
1,2
&Eva Herrmann
3
&Valentina O. Puntmann
1,2
#Springer Science+Business Media, LLC, part of Springer Nature 2018
Abstract
Purpose of Review Anti-inflammatory therapies in systemic inflammatory diseases (SID) improve disease-associated disability
and may also reduce cardiovascular events. Further optimization of treatment to directly target the inflammation affecting the
cardiovascular system represents a potential goal of contemporary treatment. Yet, lack of non-invasive means to detect cardio-
vascular involvement and to monitor the response to treatment limit such advancements. This is also reflected in the recent 2017
ESC position paper on clinical management of cardiac involvement in SIDs, whose recommendations continue to rely on
insensitive, radiation-heavy and invasive diagnostic methods. Absence of evidence and the context of a life-long chronic disease,
necessitating ongoing monitoring and serial assessments, puts such recommendations in question. The growing evidence-base
for the performance of cardiovascular magnetic resonance (CMR) in patients with SID, and especially of T1 and T2 mapping,
offers a viable pathway towards identification of cardiovascular involvement and may potentially guide cardiovascular-specific
therapies.
Recent Findings In this review, we appraise the current evidence for the role of CMR in management of cardiac involvement
patients with SID.
Summary We propose an interdisciplinary framework with a central role for CMR to support the clinical management of cardiac
involvement in SID patients.
Keywords Cardiovascular magnetic resonance .Systemic inflammatory diseases .Rheumatoid arthritis .Systemic lupus
erythematosus .Cardiac sarcoidosis .Non-ischaemic cardiomyopathy .T1 mapping .T2 mapping
Introduction
Anti-inflammatory therapies in systemic inflammatory dis-
eases (SID) have led to considerable improvement of
disease-associated symptoms and disability. Incidentally,
these novel therapies also contributed favourably towards
the reduction of cardiac morbidity and mortality, an important
outcome-defining corollary in these patients [13]. The ob-
served reduction of cardiovascular burden is auxiliary to the
anti-inflammatory treatment of the systemic disease. To target
the cardiovascular inflammatory injury directly would be the
next meaningful step, given its major impact on the overall
outcome [4]. Several issues, however, get in a way of devel-
oping cardiac-focused management pathways. Firstly, owing
to plethora of SID entities, patients are being looked after by
several medical specialties with focused attention to the sys-
temic (non-cardiac) symptoms. Secondly, the rigid routines of
classical cardiology practice, which are modelled on classical
symptoms of atherosclerotic heart disease and employ insen-
sitive methods for detection of myocardial inflammation,
make an integration of SID patients with paucity of symptoms
or rather atypical presentations particularly difficult. Thirdly,
there is a prevailingly poor grasp about the complex, dynamic
and foremost subclinical evolution of disease. The knowledge
is based on numerous case reports, a small number of
This article is part of the Topical Collection on Cardiac Magnetic
Resonance
*Valentina O. Puntmann
vppapers@icloud.com
1
Institute for Experimental and Translational Cardiovascular Imaging,
DZHK Centre for Cardiovascular Imaging, Goethe University
Hospital Frankfurt, Frankfurt am Main, Germany
2
Department of Cardiology, Goethe University Hospital Frankfurt,
Frankfurt am Main, Germany
3
DZHK Institute of Biostatistics and Mathematical Modelling at
Goethe University Frankfurt, Frankfurt am Main, Germany
Current Cardiovascular Imaging Reports (2018) 11:11
https://doi.org/10.1007/s12410-018-9451-7
systematic studies with highly selected patient groups (autop-
sy work included), allowing scattered snapshots rather than
methodological characterisation of a heterogeneous disease.
Larger outcome studies are drawn from retrospective registries
with inadequate phenotyping; cardiac involvement is com-
monly defined by results of troponin tests, echocardiography
and cardiac catheterisation, with no direct assessment of the
inflammatory vascular and myocardial tissue processes [5].
Many of these limitations have also been acknowledged in
the recent 2017 ESC position paper for management of cardi-
ac involvement in SIDs [6]. Finally, there is a central issue of
a lack of non-invasive means to effectively detect cardiovas-
cular involvement and monitor response to treatment. The
recommendations continue to rely insensitive, radiation-
heavy and invasive diagnostic methods, such as
endomyocardial biopsy (EMB), to support clinical manage-
ment. Clearly, the current recommendations are poorly
evidence-based and largely unsuitable for the use in young
patients. Moreover, the context of life-long chronic disease
necessitates long-term monitoring of inflammatory cardiac in-
volvement through serial assessments. Given that SID patients
receive anti-inflammatory treatment anyway for treatment of
systemic symptoms, these rather unappealing cardiac recom-
mendations will unlikely result in marked improvement of
cardiovascular aspects. The statement is scarce on the highly
relevant insights derived by cardiovascular magnetic reso-
nance (CMR), in particular, the potential offered by the tissue
mapping methods. As an accurate, non-invasive, radiation-
free method, CMR makes a perfect choice for detection and
monitoring of cardiovascular involvement in patients with
SID [7,8]. In this review, we reappraise the current evidence
on the role of CMR in management of patients with SID. We
propose an interdisciplinary framework for screening of
cardiac involvement in SID with a central role for CMR,
allowing the support of diagnosis and management of SID
patients.
Why Is CMR an Excellent Choice in Patients
with SID
The natural course of cardiac involvement in SIDs is for the
major part subclinical in young patients, who are also com-
monly overwhelmed by symptoms in other organ systems.
Cardiac symptoms, albeit atypical, rarely occur early in the
course of systemic disease [912]. More commonly, the first
decade following diagnosis is a period of intense systemic and
silent cardiac inflammatory involvement [5,13,14](Fig.1).
In a small proportion of patients, this would eventually culmi-
nate into manifest cardiac decompensation and death from
heart failure (with an autopsy evidence of cardiac inflamma-
tory involvement). Although the many SID entities are
characterised by pathophysiologically different auto-immune
and inflammatory mechanisms, they have somewhat similar
patterns of cardiovascular involvement. These are a result of
either direct inflammatory myocardial injurymyocarditis
[1521,22]or are mediated via vasculitic coronary or aor-
tic involvement, endothelial dysfunction and microvascular
disease [8,2326]. Evidence derived through CMR contrib-
uted a number of the unprecedented pathophysiological in-
sights, non-invasively,invivo(Table1). Firstly, it reiterated
the notion that myocardial damage is primarily caused by
myocardial inflammation (i.e. non-ischaemic in nature), by
reclassifying the ACS-like troponin-positive events without
a definite culprit lesion into protracted and indolent course
of myocarditis [15,32,33](Fig.2). Secondly, it clarified that
Manifest systemic SID
An-inflammatory therapy
SID subclinical
Awareness in
primary care Interdisciplinary approach
CMR monitoring and guiding of therapy
ongoing disease and remodelling
Cardiac morbidity and mortality in SIDs
Nave T2
Nave T1
Systemic symptoms Cardiac symptoms
CMR screening
Fig. 1 Cardiac involvement in
SID. Schematic representation of
key development stages and
overlap with systemic disease
including the proposed role for
CMR for the identification of
cardiac complications and therapy
guidance
11 Page 2 of 14 Curr Cardiovasc Imaging Rep (2018) 11:11
Table 1 Overview of studies using CMR in SID
Study SID No. of patients Native T1 SID vs.
Control
Native t2 SID vs.
Control
Field strength Main findings
Puntmann VO,
2013 [17]
SLE 33 1152 vs. 1056 ms 3 Diffuse myocardial fibrosis and ongoing inflammation shown
by T1 and T2, correlating with LGE and strain.
Zhang et al., 2014 [16] SLE 24 981 vs. 963 ms 58 vs. 52 ms 1.5 Native T2 is increased in SLE, native T1 is not different from
normal in this study.
Ntusi N, 2014 [27] SSC 191 1007 vs. 958 ms 1.5 Native T1 is increased in SSC and correlates with disease
activity and severity.
Ntusi N, 2015 [18] RA 39 973 vs. 961 msec 1.5 Increased native T1 suggests diffuse myocardial fibrosis in RA.
Barison A, 2015 [28] SSC 30 911 vs. 890msec 1.5 Native T1 is not significantly increased.
Hinojar R, 2016 [15] SLE 76 1176 vs. 1057 msec 65 vs. 45 msec 3 Native T1 and T2 are increased in SLE patients; 91% above 2SD;
71% above 5 SD in disease recognition and response to treatment.
Greulich S, 2016 [94] SARC 61 994 vs. 960 msec 52 vs. 49 msec 1,5 Native T1 and T2 display cardiac involvement in sarcoidosis.
Puntmann VO, 2017 [22] SARC 53 1139 vs. 1052 msec 54 vs.45 msec 3 T1 is a strong predictor for disease and is also increased and
treatment responsive in sarcoidosis.
Hromadka M, 2017 [95] SSC 33 1258.9 vs. 1192.2 msec 3 Asymptomatic cardiac involvement is common in SSC patients
with focal as well as diffuse myocardial fibrosis.
Wu R, 2018 [96] SLE 24 1227 vs. 1174 mesc 3 Native T1 is significantly increased in SLE.
Holmström M, 2016 [97] RA 49 1173 vs 1053 msec
1011 vs. 976msec
3
1,5
Significantly higher native T1 and T2 values describe diffuse
myocardial fibrosis and inflammation in RA patients.
Greulich S, 2017 [98] ANCA pos.
vasculitis
37 988 vs. 952 msec 53 vs. 49 msec 1,5 Native T1 and T2are increased and appear independent from
LGE in ANCA pos. vasculitis.
Microvascular disease
Study SID No. of Patients Technique Present in n(%) Main finding
Ishimori ML, 2011 [29] SLE 18 Adenosine stress
perfusion imaging
8 (44%) Microvascular disease detected by adenosine stress perfusion in SLE.
Varm a 2 01 4 [ 24] SLE 27 Adenosine stress
perfusion imaging
8(30%) Microvascular disease detected by adenosine stress perfusion in SLE.
Late Gadolinium Enhancement
Study SID No. of Patients Present in n(%) Main finding
Raman SV, 2012 [25] CSS 19 9(45%) LGE detecting cardiac involvement.
Greulich S, 2013 [21] SARC 155 40(26%) LGE as a predictor for cardiac death in SARC
Puntmann VO, 2013 [17] SLE 33 20(61%) LGE detecting subclinical cardiac involvement
Marmursztejn J, 2013 [31] CSS 20 14(70%) The presence of LGE localises subclinical active lesions, i.e.
fibrosis or ongoing inflammation.
Di Cesare E, 2013 [30] SSC 58 25(43%) LGE is a valid method to detect cardiac involvement
Ntusi N, 2014 [27] SSC 19 10(53%) LGE detecting subclinical cardiac involvement
Ntusi N, 2015 [18] RA 39 46% LGE detecting subclinical cardiac involvement
Puntmann VO, 2017 [22] SARC 54 34% LGE detecting subclinical cardiac involvement
Holmström M, 2016 [97] RA 49 55% LGE detected in combination with systolic and diastolic
impairment in RA.
Varm a 2 01 5 [ 24] SLE 27 11 (44%)
24(89%)
LGE detecting subclinical coronary vasculitis by Myocardial
LGE Diffuse coronary LGE
SLE systemic lupus erythematosus, SID systemic inflammatory disease, SSC systemic sclerosis, CCS Churg-Strauss syndrome, SARC sarcoidosis, RA rheumatoid arthritis
Curr Cardiovasc Imaging Rep (2018) 11:11 Page 3 of 14 11
a classic atherothrombotic ischaemic injury [34] is rare, as
substantiated by a prevalently absent ischaemic type of late
gadolinium enhancement (LGE) in SID patients, a gold-
standard non-invasive method to demonstrate a post-
infarction scar. Thirdly, assessment of cardiac volumes and
function using CMR is more accurate than with echocardiog-
raphy, thus allowing an early detection of cardiac enlargement
or functional deterioration. This is important, given that an
early start of anti-remodelling treatment can be rewarding
[33,35](Fig.3). Fourthly, the capabilities of CMR myocardial
perfusion imaging allow insight into the regional (spatial), but
also temporal (dynamic) information about myocardial blood
flow distribution. This capability, which is unique to CMR
[39,40], enables to reliably distinguish between classical re-
gional ischaemia due to obstructive epicardial coronary artery
disease, such as in stable angina, and diffuse circumferential
subendocardial hypoperfusion due to microvascular disease,
with endothelial dysfunction substantiating an inherent path-
ophysiological linkage between systemic and myocardial in-
flammation [41] (Fig. 4). Such distinction is an important
clinical management step in SID patients, as microvascular
dysfunction is highly prevalent, and a correct diagnosis of
microvascular dysfunction will not only offer reassurance
but also avoid the unnecessary and futile investigations, com-
monly in vain of radiation-heavy coronary catheterisations
and nuclear medicine imaging methods. Many of the above-
mentioned insights are based on the studies performed in pa-
tients with no overt cardiac symptoms and typically much
younger subjects, than routinely seen in cardiological practice
[17,18,24,2730,43]. Collectively, this new knowledge puts
in question the traditional assumption of the accelerated ath-
erosclerotic heart disease, as the main driver of cardiac in-
volvementinSID[44,45]. This may still be relevant in an
older patient with primarily vasculitic-type of SID, such as
rheumatoid arthritis; however, even in this disease-subgroup,
the subclinical inflammatory myocardial involvement is read-
ily demonstrable early in the course of systemic disease [18,
46]. The pathophysiological importance of myocardial in-
flammation has been further reinforced by novel myocardial
tissue measures, such as T1 and T2 mapping, which directly
reflect altered tissue magnetisation [47] and have been report-
ed in a number of SID conditions (Fig. 5). The potential for
improved management of cardiac involvement in SID borne
by these measures cannot be overemphasised: measurements
are obtained non-invasively in a course of short acquisitions
and without any contrast agents. T1 and T2 mapping measure-
ments reflect disease severity and, by way of serial assess-
ments, disease activity. They track the response to anti-
inflammatory treatment, thus informing on the scope for re-
versibility and recovery of cardiac involvement [15,22]
(Fig. 6). Finally, T1 mapping also strongly relates to progno-
sis; its predictive associations with outcome in non-ischaemic
cardiomyopathy strongly outperform the traditional risk mea-
sures, such as LV ejection fraction (LVEF) or the presence of
LGE [36] (Fig. 7). Taken together, these advances offer a
scope for tremendous progress and a true non-invasive man-
agement pathway, allowing a paradigm shift of clinical man-
agement from the non-sensitive, invasive and radiation-heavy
methods towards patient-friendly and safe assessments (non-
invasive, radiation-free and contrast-free), which can
Lupus
myocardis
Sarcoid
myocardis
Nave T1 1095 msec (1.5T <1000 msec )
Nave T1 1114 msec (1.5T <1000 msec )
Fig. 2 CMR findings in acute SID myocarditis. Upper panel: Acute myocarditis, lower panel: acute sarcoid myocarditis. Native 1 is strongly elevated.
Note diffuse patchy intramyocardial LGE (red/yellow arrows) corresponding to the inflammatory overspill of myocardial oedema and regional scarring
11 Page 4 of 14 Curr Cardiovasc Imaging Rep (2018) 11:11
accurately inform on the disease presence, stage and severity,
and gauge treatment response. The several advantages of
CMR for patients with SID are underscored by a single com-
mon denominatorCMR readouts can guide clinical man-
agement. The proposed CMR imaging protocols are presented
in Fig. 8.
Inflammatory CardiomyopathyT1 and T2
Mapping
Myocardial involvement in SIDs is a classical model of dif-
fuse, sustained myocardial inflammationmyocarditiswith
interchanging periods of lower and greater activity (Figs. 1
and 2). Clinical recognition of myocarditis is notoriously chal-
lenging owing to nonspecific symptoms, which in SID pa-
tients are additionally overshadowed by systemic manifesta-
tions, such as renal complications in systemic lupus erythema-
tosus (SLE) or lung involvement in systemic sarcoidosis.
Inflammatory activity is commonly at its peak within the first
decade of systemic disease. The severity of myocardial in-
volvement is well out of proportion with systemic disease
activity score and symptomatically well compensated for by
the predominately young patients [5,13,15,17,22,27]. As
such, cardiac involvement will be detected incidentally, com-
monly by way of a raised troponin during episodes of clini-
cally manifest decompensation due to acute-on chronic in-
flammatory cardiomyopathy [32,48,49][15,22,50].
Thus, a focused and systematic screening in patients with
known systemic involvement, using methods that are suffi-
ciently sensitive to detect inflammation, is mandatory. T1
and T2 mapping reveal the presence of myocardial tissue
changes due to myocardial inflammation and remodelling
with fibrosis in many SID entities, including SLE, RA, sys-
temic sclerosis and cardiac sarcoidosis (Fig. 9). The two map-
ping measures are complementary in informing on the type of
cardiac involvement in SID; while native T1 is a sensitive
indicator of abnormal cardiomyopathic tissue processes, de-
tecting substrates such as myocardial inflammation, or sar-
coid, amyloid or fatty infiltration, as well as diffuse or replace-
ment fibrosis [17,36,47,51,52], native T2 is a specific
marker of myocardial oedema/inflammation [38,53,54].
Both measures are raised in the presence of active inflamma-
tion; their values rise linearly with increased severity, whereas
SAX
4CH
Cines
LGE
Churg-Strauss related DCM
Lupus-related DCM
SAX
Cines
LGE
LGE LGE
LGE
4CH 4CH
3CH
SAX
Fig. 3 Non-ischaemic dilated cardiomyopathy in SID. Upper panel:
DCM was a coincidental finding in a young SLE patient (< 20 years of
age) undergoing a pre-kidney transplant cardiac screening. CMR revealed
dilated left ventricle (indexed EDV: 152 ml/m
2
(normal range 9862 ml/
m
2
) with severely impaired global systolic function (LVEF 20%). There
was no evidence of LGE. Biatrial dilatation indicates chronic pressure
overload due to longstanding hypertension. Native T1 was raised (at
1.5 Tesla: 1078 ms, > 4 SD [36,37]), whereas native T2 (42 ms) was
within normal range (4149 ms) [38]. Lower panel: A 45~-year-old
patient with a known diagnosis of systemic Churg-Strauss Syndrome.
Previous history includes an ACS-like presentation with unobstructed
coronary arteries and an eosinophilic myocarditis was confirmed using
an EMB 5 years prior. CMR confirmed a dilated cardiomyopathy
(indexed LV-EDV 140 ml/m
2
(normal range 5195 ml/m
2
), LVEF
26%), with preserved RV size and function, and LA dilatation. LGE
imaging revealed global subendocardial scarring (not limited to a single
coronary artery), also affecting RV. Native T1 was elevated at 1288 ms
(3.0 T: normal range < 1090 ms) [37], with native T2 of 36 (3.0 T: normal
range 3139 ms)
Curr Cardiovasc Imaging Rep (2018) 11:11 Page 5 of 14 11
Fig. 4 Macrovascular coronary artery disease - ischaemia vs.
microvascular disease): Upper panel: regional myocardial ischaemia
due to obstructive coronary artery disease in a 69- year old patient with
rheumatoid arthritis (RA) yields a perfusion defect in the right coronary
artery territory (RCA: yellow arrows). Lower panel: diffuse prolonged
circumferential (sub)endothelial hypoperfusion (yellow arrows), but
preserved and rapid epicardial opacification entry (green arrows), due to
unobstructed epicardial coronary disease and inflammation-induced
endothelial dysfunction in myocardial microvasculature in a 28-year old
patient with SLE. Reproduced from Varma et al with permission [42]
B. Sarcoid paents
A. SLE paents
Fig. 5 Native T1 in discrimination between health and subclinical disease, in patients with SLE (a) and systemic sarcoidosis (b). Reproduced from [17,
22] with permission
11 Page 6 of 14 Curr Cardiovasc Imaging Rep (2018) 11:11
drop in remission or in response to anti-inflammatory treat-
ment [50,55]. These observations impart a marked influence
of myocardial water, as either interstitial or intracellular oede-
ma. The reactivity of both measures to this inflammatory sub-
strate makes them ideal for application in monitoring of dis-
ease activity and in guiding the anti-inflammatory treatment.
The two treatment studies revealed that the greatest change in
measures in response to anti-inflammatory treatment for sys-
temic and not cardiac systems occurs soon after initiation,
reaching a plateau thereafter, suggesting that myocardial
inflammation is reduced, however, continues at a lower level
of activity [15,22]. This important observation is particularly
informative: whereas myocardial inflammation is a key path-
ological process, it however necessitates reassessment, moni-
toring and fine-tuning its treatment. These findings are com-
monly disproportionate relative to structural heart changes or
functional impairment, communicating the presence of in-
flammatory cardiomyopathy, which is readily detectable in a
large proportion of patients [9,17,27,28,54,5658]. T1
mapping does not only offer diagnostic insight but also
Fig. 6 Native T1 and T2 measurements at baselineand follow up in patients receiving intensified therapy (n= 14) and those with unchanged regime (n=
21). A black line indicates trend line in the respective groups. Reproduced from Hinojar 2016 [15] with permission
Curr Cardiovasc Imaging Rep (2018) 11:11 Page 7 of 14 11
strongly relates to prognosis. A multicentre study in non-
ischaemic cardiomyopathy, a common sequel of SID-related
inflammatory cardiomyopathy [6,59], demonstrated that the
higher the native T1 values, the more unfavourable its associ-
ation with survival, cardiac mortality and heart failure [36].
Notably, predictive association for native T1 was independent
of structural heart changes, severity of functional impairment
(LVEF) or presence of myocardial scar by LGE. Thus, by
directly linking the underlying pathological substrate and its
prognostic relevance, the information on native T1 is the sin-
gle most important measurement in patients with SID, in rec-
ognition of myocardial disease, its severity and their progno-
sis. Thus, T1 and T2 mapping may adopt a central role in
guiding the management of cardiac inflammatory involve-
ment directly, by supporting the serial assessmentswhich
are non-invasive, radiation-free and contrast freeallowing
to monitor disease activity and treatment efficacy and guiding
the necessary modifications in a life-long chronic disease
(Figs. 5and 6).
Distinction between Macro-
and Microvascular Coronary Disease in SID
The diagnosis of relevant coronary artery disease in patients
with presumed intermediate-high risk due to the influence of
systemic inflammation [60], with commonly less typical
symptoms, mandates functional assessment [61]. In the pre-
dominantly young and prevalently female SID population, the
choice of the diagnostic methods is relevant given the many
Fig. 7 Native T1 in prediction of all-cause mortality in patients with non-
ischaemic DCM. Kaplan-Meier curves forCMR parameters and all-cause
mortality (anative T1 (normal vs. abnormal myocardium, based on > 2
SD above the mean of the normal reference range [17]), bnative T1
ranked by 2n-times SD (ranks of SD < 2, 24, 46, 6 Dabir 2014
[37], cLGE present vs. absent, dLVEF < 35%. Reproduced from
Puntmann 2016 [36] with permission
11 Page 8 of 14 Curr Cardiovasc Imaging Rep (2018) 11:11
possible outcomes owing to complex pathophysiology, as
well as considerable sex differences and variation in diagnos-
tic accuracy between the methods that can be employed in
detection of relevant CAD [62,63]. To this end, myocardial
perfusion imaging with CMR offers several important advan-
tages in patients with SID: firstly, it has a higher diagnostic
and prognostic accuracy for detection of significant obstruc-
tive CAD in comparison to other non-invasive functional
methods of ischaemia testing, such as exercise treadmill or
echo testing (Fig. 4a) [6469]. Secondly, the evidence of re-
gional hypoperfusion (of more than 4/32 myocardial seg-
ments) indicates relevant obstructive coronary artery disease,
which would prognostically benefit from coronary interven-
tion, i.e. the amount of ischaemia also filters out those patients
that actually benefit from further invasive procedures [64,
7072]. Thirdly, myocardial perfusion CMR imaging is not
only highly sensitive for the diagnosis of ischaemia [73]but
also allows recognition of microvascular disease non-
CMR imaging protocol
Inial screening and every 3 years thereaer
T1 mapping T2 mapping LV and RV
Funcon
Myocardial
perfusion LGE
Interim monitoring of disease acvity and treatment response (6-months’ intervals)
30 min
15 min
T1 mapping T2 mapping LV and RV
Funcon
Fig. 8 Proposed CMR protocols, for screening (upper panel) and
monitoring (lower panel) of cardiac involvement in patients with SID.
Screening shall be performed at the time of diagnosis of SID. As these
patients are young, subsequent serial assessments should employ
primarily native (contrast-free) T1 and T2 mapping with CMR which is
a non-invasive and radiation-free method
, 2, p
Fixed effect model
Random effects model
Heterogeneity:
I2= 94% = 1648 < 0.01
Puntmann VO, 2017
Hromadka M, 2017
Study
Puntmann VO, 2013
Zhang Y, 2014
Hinojar R, 2016
Wu R, 2017
Ntusi NAB, 2015
Holmström M, 2017*
Holmström M, 2017*
Greulich S, 2016*
Ntusi NA, 2014
Barison A, 2015
Greulich S, 2017*
Total
474
33
24
76
24
39
29
20
61
53
19
30
29
37
Mean
1152.0
981.6
1176.0
1227.0
973.0
1173.0
1011.0
994.0
1139.0
1007.0
811.0
1258.9
988.0
SD
46.0
65.0
55.0
48.8
27.0
24.4
54.1
47.4
65.0
29.0
89.0
51.2
70.2
Experimental
Total
281
21
12
46
12
39
9
10
26
36
20
10
20
20
Mean
1056.0
963.9
1057.0
1174.7
961.0
1053.0
976.0
960.0
1052.0
958.0
790.0
1192.2
952.0
SD
27.0
32.0
23.0
95.8
18.0
152.6
13.3
32.6
34.0
20.0
84.0
32.6
27.4
Control
-200 -100 0 100 200
Mean Difference MD
52.56
55.70
96.00
17.70
119.00
52.30
12.00
120.00
35.00
34.00
87.00
49.00
21.00
66.70
36.00
95%-CI
[ 47.11; 58.01]
[ 31.73; 79.67]
[ 76.51; 115.49]
[-13.99; 49.39]
[104.96; 133.04]
[ -5.31; 109.91]
[ 1.82; 22.18]
[ 19.91; 220.09]
[ 9.90; 60.10]
[ 16.72; 51.28]
[ 66.27; 107.73]
[ 33.29; 64.71]
[-40.03; 82.03]
[ 43.22; 90.18]
[ 10.39; 61.61]
(fixed)
100.0%
--
7.8%
3.0%
15.1%
0.9%
28.6%
0.3%
4.7%
10.0%
6.9%
12.0%
0.8%
5.4%
4.5%
Weight
(random)
-
-
100.0%
8.6%
7.8%
8.8%
6.0%
8.9%
3.5%
8.3%
8.7%
8.5%
8.7%
5.7%
8.3%
8.2%
Weight
SLE
SLE
SLE
SLE
RA
RA
RA
SARC
SARC
SSC
SSC
SSC
ANCA+VASC
3T
1.5T
3T
3T
1.5T
3T
1.5T
1.5T
3T
1.5T
1.5T
3T
1.5T
*SD estimated
from interquartile
range
Fig. 9 Forest plot of studies using myocardial T1 mapping in patients with SID
Curr Cardiovasc Imaging Rep (2018) 11:11 Page 9 of 14 11
invasively, an important subentity of myocardial ischaemia,
which is highly prevalent in SID patient population. Thus,
patients will benefit from the definitive diagnosis, by either
subsequent intervention in regional macrovascular disease, or
reassurance from knowing that microvascular disease under-
lies their symptoms and may benefit from intensified tradi-
tional treatment [74,75]. Establishing correct diagnosis by
CMR will cut the commonly occurring vicious circle of the
over-investigation in SID patients and reduce the exposure to
radiation,nephrotoxic contrast agents and the procedural com-
plications [24,29,43,76,77].
Irreversible Cardiovascular Injury
and Advanced Disease
Most patients with SID will have normal cardiac volumes and
biventricular function [17,27,46,78]. Relative increase in LV
wall thickness due to myocardial inflammation precludes de-
tecting a small increase in LV volumes, only to become ap-
parent in the later stages. Thus, reduction of longitudinal myo-
cardial strain may be the earliest sign of left ventricular (LV)
functional impairment. As inflammation subsides, LV walls
will be thinned with contractile dysfunction, marking the tran-
sition to dilated cardiomyopathy. Increase in LV mass in early
inflammatory stages may be followed by either reduced LV
mass due to physical inactivity or increased LV mass due
DCM and HF [36,46,79,80,81]. The relatively long period
of preserved cardiac function and structure explains some of
the overall difficulty in separating the normal findings from
the abnormal, solely on the basis of cardiac structure and
function, such as with echocardiography [82,83]. Gross ab-
normalities, which eventually occur once disease has
progressed into advanced stages, add little beyond the confir-
mation of involvement with a poor scope for reversibility.
The presence of LGE is invariably a poor prognostic sign,
marking the burden of irreversible injury and advanced stage
of disease. The physiological mechanism of gadolinium tissue
uptake relates to the pathologically expanded extracellular
space, which is also regionally separated from the remaining
myocardial tissue with preserved myocyte membrane connec-
tions. This imaging phenomenon of brightness in the areas of
accumulated gadolinium contrast agent becomes apparent af-
ter a time lag of about 510 min from its administration: the
contrast agent has by then washed out from the preserved
myocardium, marking out histopathological substrates, such
as regional myocardial scar, fibrosis or extracellular oedema.
LGE is instrumental in recognition of the cardiac involvement
by way of disease-specific LGE patterns. In about a third of
patients, LGE can uncover non-ischaemic type myocardial
scar, an irreversible sequel of inflammatory injury, which
can also be unexpectedly large [9,20](Fig.10). In anti-
phospholipid syndrome or Churg-Strauss vasculitis, a suben-
docardial ischaemic-like pattern of myocardial scar is not
uncommon, yet it is a consequence of thrombo-vasculitis or
eosinophilic myocarditis, respectively, and not atherosclerosis
Case 1
Case 2
Fig. 10 LGE patterns in sarcoidosis. Representative images of myocardial scarring in cardiac involvement in systemic sarcoidosis (small scar
unexpectedly revealing the diagnosis in case 1, considerable scarring in case 2)
11 Page 10 of 14 Curr Cardiovasc Imaging Rep (2018) 11:11
[31,8486] (Fig. 3). A classic atherothrombotic ischaemic
scar is rare in SID patients and mainly concentrated to the
older group of patients with a milder course of systemic dis-
ease and fewer cardiovascular risk factors [81,83].
Conclusion: Towards Non-invasive Clinical
Management of Myocardial Inflammation
in SID
Cardiac involvement in SIDs has a major impact on pa-
tientsoutcome, yet the pathways to its recognition and
management remain poorly established [6,82]. Overall
clinical management in these patients is primarily guided
by systemic symptoms due to involvement of joints, skin,
lungs, kidneys or brain. Cardiovascular disease remains
largely undetected as it evolves through years of subclin-
ical inflammation (Fig. 1): the majority of these docu-
mented cardiac manifestations, which form the knowledge
base for a high burden of CVD in SIDs, relate to ad-
vanced disease manifestations, such as heart failure and
arrhythmic presentations. Despite increased awareness of
CVD burden in SID patients and improved insight into
the natural course of heart disease with emphasis on the
mechanistic role of the inflammatory pathways, ap-
proaches to diagnosis and management rely on relatively
insensitive, inaccurate and commonly invasive diagnostic
means. Ironically, whereas a number of major clinical tri-
als on cardiovascular inflammation in the classical cardiac
patients further substantiated the role and the need to tar-
get cardiovascular inflammation directly [87,88], similar
evidence in SID patients, where inflammation is the par-
amount physiological driver of injury and disability, is
missing [8992].
The development of an accurate and non-invasive diagnos-
tic method for identification of myocardial inflammation is
central to the evolution of effective clinical management of
inflammatory cardiomyopathy in SIDs. To this end, CMR
with T1 and T2 mapping is the key new opportunity, allowing
to decipher myocardial inflammation directly [17,50,53,54,
93]. Targeted and systematic CMR assessment of SID patients
shall start concomitantly with the diagnosis of SID, through a
comprehensive interdisciplinary screening programme,
allowing timely and direct anti-inflammatory cardiac care
(Figs. 1and 8). This will eventually provide a platform for
systematic assessment of clinical efficacy of CMR-guided in-
flammatory therapy; clinical trials testing such hypotheses are
needed, yet in a view of omni-present inflammatory therapy in
SID patients, large sample sizes will be required. Future sys-
tematic research shall also clarify the utility of the serological
biomarkers, to support development of interdisciplinary
screening programme to support timely delivery of cardiac
care in patients with SID.
Compliance with Ethical Standards
Conflict of Interest All authors declare that they have no conflicts of
interest.
Human and Animal Rights and Informed Consent This article does not
contain any studies with human or animal subjects performed by any of
the authors.
References
Papers of particular interest, published recently, have been
highlighted as:
Of importance
1. Knockaert DC. Cardiac involvement in systemic inflammatory dis-
eases. Eur Heart J. 2007;28(15):1797804.
2. Hamdulay SS, Mason JC. Disease-modifying anti-rheumatic drugs:
do they reduce cardiac complications of RA? Heart. 2009;95(18):
14712.
3. Urowitz MB, Gladman DD, Tom BDM, Ibañez D, Farewell VT.
Changing patterns in mortality and disease outcomes for patients
with systemic lupus erythematosus. J Rheumatol. 2008;35(11):
21528.
4. Douglas KMJ. Excess recurrent cardiac events in rheumatoid ar-
thritis patients with acute coronary syndrome. Ann Rheum Dis.
2006;65(3):34853.
5. Bengtsson C, Ohman ML, Nived O, Dahlqvist SR. Cardiovascular
event in systemic lupus erythematosus in northern Sweden: inci-
dence and predictors in a 7-year follow-up study. Lupus. 2012 Mar
16;21(4):4529.
6.Caforio ALP, Adler Y, Agostini C, Allanore Y, Anastasakis A, Arad
M, et al. Diagnosis and management of myocardial involvement in
systemic immune-mediated diseases: a position statement of the
European Society of Cardiology Working Group on Myocardial
and Pericardial Disease. Eur Heart J. 2017;38(35):264962. The
latest ESC position paper on myocarditis focuses on the role of
biopsy in the diagnosis of myocardial inflammation rather than
including CMR as a valid method in diagnosis and prognosis.
Furthermore, it lacks several recent CMR studies.
7. Mavrogeni SI, Kitas GD, Dimitroulas T, Sfikakis PP, Seo P, Gabriel
S, et al. Cardiovascular magnetic resonance in rheumatology: cur-
rent status and recommendations for use. Int J Cardiol.
2016;217(C):13548.
8. Gerster M, Peker E, Nagel E, Puntmann VO. Deciphering cardiac
involvement in systemic inflammatory diseases: noninvasive tissue
characterisation using cardiac magnetic resonance is key to im-
proved patientscare. Expert Rev Cardiovasc Ther. 2016;14(11):
128395.
9. Isted A, Grigoratos C, Bratis K, Carr-White G, Nagel E, Puntmann
VO. Native T1 in deciphering the reversible myocardial inflamma-
tion in cardiac sarcoidosis with anti-inflammatory treatment. Int J
Cardiol. 2016;203:45962.
10. Mavrogeni S, Karabela G, Stavropoulos E, Plastiras S, Spiliotis G,
Gialafos E, et al. Heart failure imaging patterns in systemic lupus
erythematosus. Evaluation using cardiovascular magnetic reso-
nance. Int J Cardiol. 2014;176(2):55961.
11. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger
VRL, Jacobsen SJ, et al. Increased unrecognized coronary heart
disease and sudden deaths in rheumatoid arthritis: a population-
based cohort study. Arthritis Rheum. 2005;52(2):40211.
Curr Cardiovasc Imaging Rep (2018) 11:11 Page 11 of 14 11
12. Nicola PJ, Maradit-Kremers H, Roger VRL, Jacobsen SJ, Crowson
CS, Ballman KV, et al. The risk of congestive heart failure in rheu-
matoid arthritis: a population-based study over 46 years. Arthritis
Rheum. 2005;52(2):41220.
13. Palmieri V, Migliaresi P, Orefice M, Lupo T, Di Minno MND,
Valentini G, et al. High prevalence of subclinical cardiovascular
abnormalities in patients with systemic lupus erythematosus in spite
of a very low clinical damage index. Nutr Metab Cardiovasc Dis.
2009;19(4):23440.
14. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jansen-
McWilliams L, et al. Age-specific incidence rates of myocardial
infarction and angina in women with systemic lupus erythematosus:
comparison with the Framingham Study. Am J Epidemiol.
1997;145(5):40815.
15. Hinojar R, Foote L, Sangle S, Marber M, Mayr M, Carr-White G,
et al. Native T1 and T2 mapping by CMR in lupus myocarditis:
disease recognition and response to treatment. Int J Cardiol.
2016;222:71726.
16. Zhang Y, Corona-Villalobos CP, Kiani AN, Eng J, Kamel IR,
Zimmerman SL, et al. Myocardial T2 mapping by cardiovascular
magnetic resonance reveals subclinical myocardial inflammation in
patients with systemic lupus erythematosus. Int J Cardiovasc
Imaging. 2014;31(2):38997.
17. Puntmann VO, DCruz D, Smith Z, Pastor A, Choong P, Voigt T,
et al. Native myocardial T1 mapping by cardiovascular magnetic
resonance imaging in subclinical cardiomyopathy in patients with
systemic lupus erythematosus. Circulation: Cardiovascular
Imaging. 2013;6(2):295301.
18. Ntusi NAB, Piechnik SK, Francis JM, Ferreira VM, Matthews PM,
Robson MD, et al. Diffuse myocardial fibrosis and inflammation in
rheumatoid arthritis. J Am Coll Cardiol Img. 2015;8(5):52636.
19. Mavrogeni S, Spargias C, Bratis C, Kolovou G, Markussis V,
Papadopoulou E, et al. Myocarditis as a precipitating factor for
heart failure: evaluation and 1-year follow-up using cardiovascular
magnetic resonance and endomyocardial biopsy. Eur J Heart Fail.
2011;13(8):8307.
20. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA,
et al. Detection of myocardial damage in patients with sarcoidosis.
Circulation. 2009;120(20):196977.
21. Greulich S, Deluigi CC, Gloekler S, Wahl A, Zürn C, Kramer U,
et al. CMR imaging predicts death and other adverse events in
suspected cardiac sarcoidosis. J Am Coll Cardiol Img. 2013;6(4):
50111.
22.Puntmann VO, Isted A, Hinojar R, Foote L, Carr-White G, Nagel E.
T1 and T2 mapping in recognition of early cardiac involvement in
systemic sarcoidosis. Radiology. 2017;162732. T1 mapping de-
tects early stages of myocardial involvement in systemic sar-
coidosis and is overall a reliable marker for inflammatory re-
versibility upon usage of CMR imaging-based treatment.
23. Puntmann VO, Bigalke B, Nagel E. Characterization of the inflam-
matory phenotype in atherosclerosis may contribute to the develop-
ment of new therapeutic and preventative interventions. Trends in
Cardiovascular Medicine. 2010;20(5):17681.
24. Varma N, Hinojar R, DCruz D, Arroyo Ucar E, Indermuehle A,
Peel S, et al.Coronary vessel wall contrast enhancement imaging as
a potential direct marker of coronary involvement. J Am Coll
Cardiol Img. 2014;7(8):76270.
25. Raman SV, Aneja A, Aneja A, Jarjour WN, Jarjour WN. CMR in
inflammatory vasculitis. J Cardiovasc Magn Reson [Internet].
2012;14(1):82. https://doi.org/10.1186/1532-429X-14-82.
26. Keenan NG, Mason JC, Maceira A, Assomull R, OHanlon R,
Chan C, et al. Integrated cardiac and vascular assessment in
Takayasu arteritis by cardiovascular magnetic resonance. Arthritis
Rheum. 2009;60(11):35019.
27. Ntusi NA, Piechnik SK, Francis JM, Ferreira VM, Rai AB,
Matthews PM, et al. Subclinical myocardial inflammation and
diffuse fibrosis are common in systemic sclerosisa clinical study
using myocardial T1-mapping and extracellular volume quantifica-
tion. J Cardiovasc Magn Reson. 2014;16(1):21.
28. Barison A, Gargani L, De Marchi D, Aquaro GD, Guiducci S,
Picano E, et al. Early myocardial and skeletal muscle interstitial
remodelling in systemic sclerosis: insights from extracellular vol-
ume quantification using cardiovascular magnetic resonance. Eur
Heart J - Cardiovasc Imaging. 2015;16(1):7480.
29. Ishimori ML, Martin R, Berman DS, Goykhman P, Shaw LJ,
Shufelt C, et al. Myocardial ischemia in the absence of obstructive
coronary artery disease in systemic lupus erythematosus. J Am Coll
Cardiol Img. 2011;4(1):2733.
30. Di Cesare E, Battisti S, Di Sibio A, Cipriani P, Giacomelli R,
Liakouli V, et al. Early assessment of sub-clinical cardiac involve-
ment in systemic sclerosis (SSc) using delayed enhancement cardi-
ac magnetic resonance (CE-MRI). Eur J Radiol. 2013;82(6):e268
73.
31. Marmursztejn J, Guillevin L, Trebossen R, Cohen P, Guilpain P,
Pagnoux C, et al. Churg-Strauss syndrome cardiac involvement
evaluated by cardiac magnetic resonance imaging and positron-
emission tomography: a prospective study on 20 patients.
Rheumatology (Oxford). 2013;52(4):64250.
32. Appenzeller S, Pineau C, Clarke A. Acute lupus myocarditis: clin-
ical features and outcome. Lupus. 2011;20(9):9818.
33. Ishimori ML, Agarwal M, Ng RK, Nugent LD, Wallace DJ, Siegel
RJ, et al. Lupus cardiomyopathy: a reversible form of left ventric-
ular dysfunction. Arthritis Res Ther. 2012;14(Suppl 3):A61.
34. Bruce IN. Not only...but also: factors that contribute to accelerat-
ed atherosclerosis and premature coronary heart disease in systemic
lupus erythematosus. Rheumatology. 2005;44(12):1492502.
35. Ishimori ML, Agarwal M, Beigel R, Ng RK, Firooz N, Weisman
MH, et al. Systemic lupus erythematosus cardiomyopathya case
series demonstrating a reversible form of left ventricular dysfunc-
tion. Echocardiography. 2013;31(5):5638.
36. Puntmann VO, Carr-White G, Jabbour A, Yu C-Y, Gebker R, Kelle
S, et al. T1-mapping and outcome in nonischemic cardiomyopathy.
J Am Coll Cardiol Img. 2016;9(1):4050.
37. Dabir D, Child N, Kalra A, Rogers T, Gebker R, Jabbour A, et al.
Reference values for healthy human myocardium using a T1 map-
ping methodology: results from the international T1 multicenter
cardiovascular magnetic resonance study. J Cardiovasc Magn
Reson. 2014;16(1):34.
38. Hinojar R, Foote L, Cummins C, Higgins DM, Nagel E, Puntmann
V. Standardised postprocessing of native T2 in detection and dis-
crimination of myocarditiscomparison with native T1 mapping. J
Cardiovasc Magn Reson. 2016;18(Suppl 1):O14.
39. Marinescu MA, Löffler AI, Ouellette M, Smith L, Kramer CM,
Bourque JM. Coronary microvascular dysfunction, microvascular
angina, and treatment strategies. JCMG. 2015;8(2):21020.
40. Nagel E. Taking the last hurdles: magnetic resonance myocardial
perfusion imaging. JACC Cardiovasc Imaging. 2009;2(4):4346.
41. Recio-Mayoral A, Mason JC, Kaski JC, Rubens MB, Harari OA,
Camici PG. Chronic inflammation and coronary microvascular dys-
function in patients without risk factors for coronary artery disease.
Eur Heart J. 2009;30(15):183743.
42. Fichtlscherer S, Rossig L, Breuer S, Vasa M, Dimmeler S, Zeiher
AM. Tumor necrosis factor antagonism with etanercept improves
systemic endothelial vasoreactivity in patients with advanced heart
failure. Circulation. 2001;104(25):30235.
43. Ishimori ML, Anderson L, Weisman MH, Mehta PK, Bairey Merz
CN, Wallace DJ. Microvascular angina: an underappreciated cause
of SLE chest pain. J Rheumatol. 2013;40(5):7467.
44. Pasceri V, Yeh ETH. A tale of two diseases : atherosclerosis and
rheumatoid arthritis. Circulation. 1999;100(21):21246.
11 Page 12 of 14 Curr Cardiovasc Imaging Rep (2018) 11:11
45. Symmons DPM, Gabriel SE. Epidemiology of CVD in rheumatic
disease, with a focus on RA and SLE. Nat Rev Rheumatol.
2011;7(7):399408.
46. Puntmann VO, Taylor PC, Barr A, Schnackenburg B, Jahnke C,
Paetsch I. Towards understanding the phenotypes of myocardial
involvement in the presence of self-limiting and sustained systemic
inflammation: a magnetic resonance imaging study. Rheumatology.
2010 Feb 11;49(3):52835.
47. Puntmann VO, Peker E, Chandrashekhar Y, Nagel E. T1 mapping
in characterizing myocardial disease. Circ Res. 2016;119(2):277
99.
48. Zawadowski G, Klarich K, Moder K, Edwards W, Cooper L. A
contemporary case series of lupus myocarditis. Lupus.
2012;21(13):137884.
49. Bohnen S, Radunski UK, Lund GK, Kandolf R, Stehning C,
Schnackenburg B, et al. Performance of T1 and T2 mapping car-
diovascular magnetic resonance to detect active myocarditis in pa-
tients with recent-onset heart failure. Circulation: Cardiovascular
Imaging. 2015;8(6):e003073.
50.Hinojar R, Foote L, Arroyo Ucar E, Jackson T, Jabbour A, Yu C-Y,
et al. Native T1 in discrimination of acute and convalescent stages
in patients with clinical diagnosis of myocarditis. J Am CollCardiol
Img. 2015;8(1):3746. This study reveals the difference of acute
and chronic disease by CMR imaging. It specially focuseson T1
and T2 mapping as markers of inflammatory activity and dis-
ease stages.
51. Puntmann VO, Voigt T, Chen Z, Mayr M, Karim R, Rhode K, et al.
Native T1 mapping in differentiation of normal myocardium from
diffuse disease in hypertrophic and dilated cardiomyopathy. J Am
Coll Cardiol Img. 2013;6(4):47584.
52. Hinojar R, Varma N, Child N, Goodman B, Jabbour A, Yu
C-Y, et al. T1 mapping in discrimination of hypertrophic
phenotypes: hypertensive heart disease and hypertrophic
cardiomyopathyclinical perspective. Circulation:
Cardiovascular Imaging. 2015;8(12):e003285.
53. Giri S, Chung Y-C, Merchant A, Mihai G, Rajagopalan S, Raman
SV, et al. T2 quantification for improved detection of myocardial
edema. J Cardiovasc Magn Reson. 2009;11(1):56.
54. Lurz P, Luecke C, Eitel I, Föhrenbach F, Frank C, Grothoff M, et al.
Comprehensive cardiac magnetic resonance imaging in patients
with suspected myocarditis. J Am Coll Cardiol. 2016;67(15):
180011.
55. von Knobelsdorff-Brenkenhoff F, Schüler J, Dogangüzel S,
Dieringer MA, Rudolph A, Greiser A, et al. Detection and moni-
toring of acute myocarditis applying quantitative cardiovascular
magnetic resonance. Circulation: Cardiovascular Imaging.
2017;10(2):e005242.
56. Hachulla A-L, Launay D, Gaxotte V, de Groote P, Lamblin N,
Devos P, et al. Cardiac magnetic resonance imaging in systemic
sclerosis: a cross-sectional observational study of 52 patients. Ann
Rheum Dis. 2009;68(12):187884.
57. Radunski UK, Lund GK, Stehning C, Schnackenburg B, Bohnen S,
Adam G, et al. CMR in patients with severe myocarditis. J Am Coll
Cardiol Img. 2014;7(7):66775.
58. Child N, Suna G, Dabir D, Yap ML, Rogers T, Kathirgamanathan
M, et al. Comparison of MOLLI, shMOLLLI, and SASHA in dis-
crimination between health and disease and relationship with histo-
logically derived collagen volume fraction. Eur Heart J Cardiovasc
Imaging. 2017.
59. Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J,
Felix SB, et al. Current state of knowledge on aetiology, diagnosis,
management, and therapy of myocarditis: a position statement of
the European Society of Cardiology Working Group on Myocardial
and Pericardial Diseases. Eur Heart J. 2013;34(33):263648.
60. Authors/Task Force members, Perk J, De Backer G, Gohlke H,
Graham I, Verschuren M, et al. European guidelines on
cardiovascular disease prevention in clinical practice (version
2012): The Fifth Joint Task Force of the European Society of
Cardiology and Other Societies on Cardiovascular Disease
Prevention in Clinical Practice (constituted by representatives of
nine societies and by invited experts) * Developed with the special
contribution of the European Association for Cardiovascular
Prevention & Rehabilitation (EACPR). Eur Heart J. 2012;33(13):
1635701.
61. 2013 ESC guidelines on the management of stable coronary artery
disease. Eur Heart J. 2013;34(38):29493003.
62. Shaw LJ, Olson MB, Kip K, Kelsey SF, Johnson BD, Mark DB,
et al. The value of estimated functional capacity in estimating out-
come. J Am Coll Cardiol. 2006;47(3):S3643.
63. Bairey Merz CN, Shaw LJ, Reis SE, Bittner V, Kelsey SF, Olson M,
et al. Insights from the NHLBI-sponsored Womens Ischemia
Syndrome Evaluation (WISE) Study. J Am Coll Cardiol.
2006;47(3):S219.
64. Nagel E. Magnetic resonance perfusion measurements for the non-
invasive detection of coronary artery disease. Circulation.
2003;108(4):4327.
65. Schwitter J, Wacker CM, van Rossum AC, Lombardi M, Al-Saadi
N, Ahlstrom H, et al. MR-IMPACT: comparison of perfusion-
cardiac magnetic resonance with single-photon emission computed
tomography for the detection of coronary artery disease in a
multicentre, multivendor, randomized trial. Eur Heart J.
2008;29(4):4809.
66. Schwitter J, Wacker CM, Wilke N, Al-Saadi N, Sauer E, Huettle K,
et al. MR-IMPACT II: Magnetic Resonance Imaging for
Myocardial Perfusion Assessment in Coronary artery disease
Trial: perfusion-cardiac magnetic resonance vs. single-photon emis-
sion computed tomography for the detection of coronary artery
disease: a comparative multicentre, multivendor trial. Eur Heart J.
2013;34(10):77581.
67. Greenwood JP, Maredia N, Younger JF, Brown JM, Nixon J,
Everett CC, et al. Cardiovascular magnetic resonance and single-
photon emission computed tomography for diagnosis of coronary
heart disease (CE-MARC): a prospective trial. Lancet.
2012;379(9814):45360.
68. Jaarsma C, Leiner T, Bekkers S, Crijns H, Wildberger J, Nagel E,
et al. Diagnostic performance of PET, SPECT and CMR perfusion
imaging for the detection of significant coronary artery diseasea
meta-analysis. J Cardiovasc Magn Reson. 2011;13(Suppl 1):P75.
69. Jaarsma C, Leiner T, Bekkers SC, Crijns HJ, Wildberger JE, Nagel
E, et al. Diagnostic performance of noninvasive myocardial perfu-
sion imaging using single-photon emission computed tomography,
cardiac magnetic resonance, and positron emission tomography im-
aging for the detection of obstructive coronary artery disease. J Am
Coll Cardiol. 2012;59(19):171928.
70. Kelle S, Roes SD, Klein C, Kokocinski T, de Roos A, Fleck E, et al.
Prognostic value of myocardial infarct size and contractile reserve
using magnetic resonance imaging. J Am Coll Cardiol.
2009;54(19):17707.
71. Nagel E, Shaw LJ. The assessment of ischaemic burden: thoughts
on definition and quantification. Eur Heart J - Cardiovasc Imaging.
2014;15(6):6101.
72. Shaw LJ, Berman DS, Picard MH, Friedrich MG, Kwong RY,
Stone GW, et al. Comparative definitions for moderate-severe is-
chemia in stress nuclear, echocardiography, and magnetic reso-
nance imaging. J Am Coll Cardiol Img. 2014;7(6):593604.
73. Greenwood JP, Motwani M, Maredia N, Brown JM, Everett CC,
Nixon J, et al. Comparison of cardiovascular magnetic resonance
and single-photon emission computed tomography in women with
suspected coronary artery disease from the Clinical Evaluation of
Magnetic Resonance Imaging in Coronary Heart Disease (CE-
MARC) Trial. Circulation. 2014;129(10):112938.
Curr Cardiovasc Imaging Rep (2018) 11:11 Page 13 of 14 11
74. Arroyo-Espliguero R. Microvascular dysfunction in cardiac syn-
drome X: the role of inflammation. Can Med Assoc J.
2006;174(13):1833.
75. Mehta PK, Goykhman P, Thomson LEJ, Shufelt C, Wei J, Yang Y,
et al. Ranolazine improves angina in women with evidence of myo-
cardial ischemia but no obstructive coronary artery disease. J Am
Coll Cardiol Img. 2011;4(5):51422.
76. Puntmann VO, DCruz D, Taylor PC, Hussain T, Indermuhle A,
Butzbach B, et al. Contrast enhancement imaging in coronary ar-
teries in SLE. J Am Coll Cardiol Img. 2012;5(9):9624.
77. Faccini A, Kaski JC, Camici PG. Coronary microvascular dysfunc-
tion in chronic inflammatory rheumatoid diseases. Eur Heart J.
2016;37(23):1799806.
78. Ntusi NA, Piechnik SK, Francis JM, Ferreira VM, Matthews PM,
Robson MD, et al. Diffuse myocardial fibrosis is associated with
impaired myocardial strain and disease activity in rheumatoid ar-
thritis: a cardiovascular magnetic resonance study. J Cardiovasc
Magn Reson. 2014;16(Suppl 1):P292.
79.Puntmann VO, Arroyo Ucar E, Hinojar Baydes R, Ngah NB, Kuo
YS, Dabir D, et al. Aortic stiffness and interstitial myocardial fibro-
sis by native T1 are independently associated with left ventricular
remodeling in patients with dilated cardiomyopathy. Hypertension.
2014;64(4):7628. T1 mapping is remarkably increased in pa-
tients with dilated cardiomyopathy describing interstitial myo-
cardial fibrosis. It is also related to aortic stiffness shown by a
strikingly higher pulse wave velocity.
80. Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al.
Association of fibrosis with mortality and sudden cardiac death in
patients with nonischemic dilated cardiomyopathy. JAMA.
2013;309(9):896908.
81. Mavrogeni S, Sfikakis PP, Gialafos E, Bratis K, Karabela G,
Stavropoulos E, et al. Cardiac tissue characterization and the diag-
nostic value of cardiovascular magnetic resonance in systemic con-
nective tissue diseases. Arthritis Care Res. 2013;66(1):10412.
82. Mavrogeni SI, Kitas GD, DimitroulasT, Sfikakis PP, Seo P, Gabriel
S, et al. Cardiovascular magnetic resonance in rheumatology: cur-
rent status and recommendations for use. Int J Cardiol. 2016;217:
13548.
83. ONeill SG, Woldman S, Bailliard F, Norman W, McEwan J,
Isenberg DA, et al. Cardiac magnetic resonance imaging in patients
with systemic lupus erythematosus. Ann Rheum Dis. 2009;68(9):
147881.
84. Eyler AE, Ahmad FA, Jahangir E. Magnetic resonance imaging of
the cardiac manifestations of Churg-Strauss. JRSM Open. SAGE
PublicationsSage UK: London, England; 2014;5(4):
2054270414525370.
85. Mavrogeni S, Karabela G, Gialafos E, Stavropoulos E, Spiliotis G,
Katsifis G, et al. Cardiac involvement in ANCA (+) and ANCA (-)
Churg-Strauss syndrome evaluated by cardiovascular magnetic res-
onance. Inflamm Allergy Drug Targets. 2013;12(5):3227.
86. van Leuven SI, Franssen R, Kastelein JJ, Levi M, Stroes ESG, Tak
PP. Systemic inflammation as a risk factor for atherothrombosis.
Rheumatology. 2008;47(1):37.
87. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH,
Ballantyne C, et al. Antiinflammatory therapy with canakinumab
for atherosclerotic disease. N Engl J Med. 2017;377(12):111931.
88. Ridker PM. From C-reactive protein to Interleukin-6 to Interleukin-
1: moving upstream to identify novel targets for Atheroprotection.
Circ Res. 2016;118(1):14556.
89. McInnes IB, Thompson L, Giles JT, Bathon JM, Salmon JE,
Beaulieu AD, et al. Effect of interleukin-6 receptor blockade on
surrogates of vascular risk in rheumatoid arthritis: MEASURE, a
randomised, placebo-controlled study. Ann Rheum Dis.
2015;74(4):694702.
90. Hurlimann D. Anti-tumor necrosis factor-alpha treatment improves
endothelial function in patients with rheumatoid arthritis.
Circulation. 2002;106(17):21847.
91. Maki-Petaja KM, Elkhawad M, Cheriyan J, Joshi FR, Ostor AJK,
Hall FC, et al. Anti-tumor necrosis factor- therapy reduces aortic
inflammation and stiffness in patients with rheumatoid arthritis.
Circulation. 2012;126(21):247380.
92. Maki-Petaja KM. Rheumatoid arthritis is associated with increased
aortic pulse-wave velocity, which is reduced by anti-tumor necrosis
factor- therapy. Circulation. 2006;114(11):118592.
93. Ferreira VM, Piechnik SK, DallArmellina E, Karamitsos TD,
Francis JM, Choudhury RP, et al. Non-contrast T1-mapping detects
acute myocardial edema with high diagnostic accuracy: a compar-
ison to T2-weighted cardiovascular magnetic resonance. J
Cardiovasc Magn Reson. 2012;14(1):42.
94. Greulich S1, Kitterer D1, Latus J1, Aguor E1, Steubing H1,
Kaesemann P1, Patrascu A1, Greiser A1, Groeninger S1, Mayr
A1, Braun N1, Alscher MD1, Sechtem U1, Mahrholdt H2.
Comprehensive Cardiovascular Magnetic Resonance Assessment
in Patients With Sarcoidosis and Preserved Left Ventricular
Ejection Fraction. Circ Cardiovasc Imaging. 2016;9(11). pii:
e005022
95. Hromádka M1, Seidlerová J2, Suchý D3, Rajdl D4, Lhotský J1,
Ludvík J5, Rokyta R1, BaxaJ5. Myocardial fibrosis detected by
magnetic resonance in systemic sclerosis patients -Relationship
with biochemical and echocardiography parameters. Int J Cardiol.
2017;249:448-453. https://doi.org/10.1016/j.ijcard.
96. Wu R1, An DA1, Hu J2, Jiang M3, Guo Q4, Xu JR1, Wu LM1. The
apparent diffusioncoefficient is strongly correlated with extracellu-
lar volume, a measure of myocardial fibrosis,and subclinical car-
diomyopathy in patients with systemic lupus erythematosus. Acta
Radiol. 2018;59(3):287-295. https://doi.org/10.1177/
028418511771776.
97. Holmström M, Koivuniemi R, Korpi K, Kaasalainen T, Laine M,
Kuuliala, Leirisalo-Repo M,Kupari M, Kivistö S. Cardiac magnetic
resonance imaging reveals frequent myocardialinvolvement and
dysfunction in active rheumatoid arthritis. Clin Exp Rheumatol
2016;34(3):416-23
98. Greulich S, Mayr A, Kitterer D, Latus J, Henes J, Steubing H,
Kaesemann P, Patrascu A,Greiser A, Groeninger S, Braun N,
Alscher MD, Sechtem U, Mahrholdt H. T1 and T2 mappingfor
evaluation of myocardial involvement in patients with ANCA-as-
sociated vasculitides. JCardiovasc Magn Reson. 2017;19(1):6
11 Page 14 of 14 Curr Cardiovasc Imaging Rep (2018) 11:11
  • ... Thus, the discovery of biological markers having the ability to better stratify CV risks in SLE patients is warranted. In recent years, several studies demonstrated that HScTnT can be used for the stratification and prediction of future CV events and detect subclinical atherosclerosis in the general population who are apparently asymptomatic to CVD [6,8,12,13]. The aim of this study was to determine the role of HS-cTnT as a biomarker to detect subclinical coronary atherosclerosis among SLE patients who are at an apparently low risk for CVD according to traditional risk factors. ...
    Article
    Full-text available
    Aim of the work To determine the role of high sensitivity cardiac troponin T (HS cTnT) in subclinical coronary atherosclerosis in SLE patients at an apparent low risk for CVD according to traditional risk factors. Patients and methods The presence of subclinical coronary atherosclerosis was assessed by non-contract coronary computerized tomography and calcium score was measured using Agatston score in 30 SLE patients asymptomatic for CVD and 30 age and sex matched apparently healthy controls. SLE disease activity index (SLEDAI) was assessed. Serum HScTnT concentration was measured using enzyme-linked immunosorbent assay (ELISA). Results The mean age of the patients was 33 ± 5.7 years, disease duration of 33.7 ± 22 months and mean SLEDAI 8.1 ± 5.02. The mean HS cTnT level was 12.8 ± 11.3 ng/L (1–36 ng/L). Their Framingham score was 4.8 ± 3.1 (1–12). Framingham score was low in both SLE patients (range 1–12%) and controls (1–9%) (p = 0.12). 11 (36.7%) patients, but none of the controls, had coronary artery calcification (CAC). Serum HScTnT concentration was detectable (>3 ng/L) in 16 (53.3%) patients and 2 (6.7%) control (p < 0.001). Interestingly, it was detectable in all patients with CAC, but in only 26.3% of patients without (p < 0.001). HScTnT significantly correlated with Agatston (r = 0.63, p = 0.04), with erythrocyte sedimentation rate (r = −0.65, p = 0.03), and with C-reactive protein (r = 0.76, p = 0.03) in SLE patients with CAC. Conclusion Serum HScTnT level is high and associated with CAC in SLE patients who are at an apparently low risk for CVD according to the Framingham risk score. HS cTnT may be a useful biomarker for SLE-associated subclinical atherosclerosis.
  • ... Only a small proportion of patients eventually proceed into manifest cardiac disease, most commonly congestive heart failure, which is poorly reversible and difficult to treat. [4][5][6][7][8] Underscored by the pathophysiological pathways of inflammation and remodelling, CV involvement is phenotypically characterised by non-ischaemic cardiomyopathy, and coronary and aortic vasculitis. 2 9-14 A number of previous studies using cardiovascular magnetic resonance (CMR) reported significantly elevated non-invasive quantifiable myocardial tissue measures of remodelling and inflammation T1 and T2 mapping, and myocardial scar by late gadolinium enhancement (LGE), respectively (reviewed in refs 9 10 15-21 ). Studies further demonstrated considerable vascular involvement in SLE, including carotid, aortic and coronary vessel wall vasculitis, and high frequency of myocardial microvascular disease and myocardial fibrosis. ...
    Article
    Full-text available
    Background Cardiovascular (CV) involvement in patients with systemic lupus erythematosus (SLE) is presumably subclinical for the major part of its evolution. We evaluated the associations between high-sensitive troponin T (hs-TropT), a sensitive marker of myocardial injury, and CV involvement using cardiac magnetic resonance (CMR). Methods and results This is a two-centre (London and Frankfurt) CMR imaging study at 3.0 Tesla of consecutive 92 patients with SLE free of cardiac symptoms, undergoing screening for cardiac involvement. Venous samples were drawn and analysed post-hoc for cardiac biomarkers, including hs-TropT, high-sensitive C reactive protein and N-terminal pro brain natriuretic peptide. Compared with age-matched/gender-matched non-SLE controls (n=78), patients had significantly raised cardiac biomarker levels, native T1 and T2, aortic and ventricular stiffness, and reduced global longitudinal strain (p<0.01). In SLE, hs-TropT was significantly and independently associated with native T2, followed by the models including native T1 and aortic stiffness (Χ² 0.462, p<0.01). There were no relationships between hs-TropT and age, gender, CV risk factors, duration of systemic disease, cardiac structure or function, or late gadolinium enhancement. Conclusions Patients with SLE have a high prevalence of subclinical myocardial injury as demonstrated by raised high-sensitive troponin levels. CMR with T2 mapping reveals myocardial oedema as the strongest predictor of hs-TropT release, underscoring the inflammatory interstitial remodelling as the main mechanism of injury. Patients without active myocardial inflammation demonstrate diffuse interstitial remodelling and increased vascular stiffness. These findings substantiate the role of CMR in screening of subclinical cardiac involvement. Trial registration numer NCT02407197; Results.
  • Article
    Systemic immune-mediated diseases (SIDs) include autoimmune and autoinflammatory diseases (AD) affecting at least two-organ systems.1 Autoinflammatory diseases refer to a growing family of conditions characterised by episodes of unprovoked inflammation in the absence of high autoantibody titres or auto reactive T lymphocytes, reflecting a primary innate immune system dysfunction.1 Conversely, autoimmune diseases are characterised by aberrant B, T and dendritic cell responses, leading to a break in tolerance against self-antigens, with predominantly cell-mediated or autoantibody-mediated responses in genetically susceptible individuals.2–11 Autoantibodies (AAbs), when detectable, can promote inflammatory responses via immune complex formation and may directly affect target organ function,10 e.g. resulting, in cardiac autoimmunity, in electrical disturbance, cardiomyocyte dysfunction or loss and heart failure.12–15 However, a dichotomous classification does not reflect clinical evidence and a continuum from purely autoinflammatory to purely autoimmune diseases should be considered (Figure 1).1
  • Article
    Full-text available
    Aims: To determine the bioequivalence of several T1 mapping sequences in myocardial characterization of diffuse myocardial fibrosis. Methods and results: We performed an intra-individual sequence comparison of three types of T1 mapping sequences [MOdified Look-Locker Inversion recovery (MOLLI), Shortened MOdified Look-Locker Inversion recovery ((sh)MOLLI), and SAturation recovery single-SHot Acquisition (SASHA)]. We employed two model diseases of diffuse interstitial fibrosis [patients with non-ischaemic dilated cardiomyopathy (NIDCM), n = 32] and aortic stenosis [(AS), n = 25)]. Twenty-six healthy individuals served as controls. Relationship with collagen volume fraction (CVF) was assessed using endomyocardial biopsies (EMB) intraoperatively in 12 AS patients. T2 mapping (GraSE) was also performed. Myocardial native T1 with MOLLI and shMOLLI showed, firstly, an excellent discriminatory accuracy between health and disease [area under the curves (P-value): 0.94 (0.88-0.99); 0.87 (0.79-0.94); 0.61 (0.49-0.72)], secondly, relationship between histological CVF [native T1 MOLLI vs. shMOLLI vs. SASHA: r = 0.582 (P = 0.027), r = 0.524 (P = 0.046), r = 0.443 (P = 0.150)], and thirdly, with native T2 [r = 0.628(P < 0.001), r = 0.459 (P = 0.003), r = 0.211 (P = 0.083)]. The respective relationships for extracellular volume fraction with CVF [r = 0.489 (P = 0.044), r = 0.417 (0.071), r = 0.353 (P = 0.287)] were significant for MOLLI, but not other sequences. In AS patients, native T2 was significantly higher compared to controls, and associated with levels of C-reactive protein and troponin. Conclusion: T1 mapping sequences differ in their bioequivalence for discrimination between health and disease as well as associations with diffuse myocardial fibrosis.
  • Article
    Full-text available
    Background Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Results At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P=0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P=0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P=0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P=0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P=0.31). Conclusions Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.)
  • Article
    Full-text available
    Purpose To determine whether quantitative tissue characterization with T1 and T2 mapping supports recognition of myocardial involvement in patients with systemic sarcoidosis. Materials and Methods Fifty-three consecutive patients with a biopsy-proven extracardiac diagnosis of systemic sarcoidosis (21 men; median age, 45 years; interquartile range, 22 years) and 36 normotensive previously healthy control subjects (14 men; median age, 43 years; interquartile range, 18 years) underwent cardiovascular magnetic resonance imaging, which was performed to assess cardiac function and late gadolinium enhancement, and T1 and T2 mapping. A follow-up substudy was performed in 40 patients (mean follow-up interval, 144 days ± 35 [standard deviation]); of these 40 patients, 18 underwent anti-inflammatory treatment for systemic symptoms. Binary logistic regression and receiver operating characteristic curve analyses were used to assess discrimination between health and disease; Wilcoxon signed rank test was used to assess the effect of treatment. Results When compared with control subjects, patients had higher ventricular volume, higher myocardial native T1 and T2, and lower longitudinal strain and ejection fraction (P < .05 for all). Myocardial native T1 and T2 had higher discriminatory accuracy (area under the receiver operating characteristic curve [AUC]: 0.96 and 0.89, respectively) for separation between control subjects and patients when compared with the standard diagnostic criteria (AUC < 0.67). Native T1 was the independent discriminator between health and disease (specificity, 90%; sensitivity, 96%; accuracy, 94%). There was a significant reduction of native T1 and T2 in the patients who underwent treatment (z score: -3.72 and -2.88; P < .01) but not in the patients who did not (z score, -1.42 and -1.38; P > .15). Conclusion Quantitative myocardial tissue characterization with T1 and T2 mapping may enable noninvasive recognition of cardiac involvement and activity of myocardial inflammation in patients with systemic sarcoidosis. Future studies will be performed to confirm their role in risk stratification and guidance of clinical management. (©) RSNA, 2017 Online supplemental material is available for this article.
  • Article
    Background: Cardiovascular magnetic resonance based on the Lake Louise Criteria is used to make the diagnosis of acute myocarditis. Novel quantitative parametric mapping techniques promise to overcome some of its limitations. We aimed to evaluate quantitative cardiovascular magnetic resonance to detect and monitor acute myocarditis. Methods and results: Eighteen patients with clinical diagnosis of acute myocarditis (25 years [23-38 years]; 78% males) were prospectively enrolled and repeatedly underwent cardiovascular magnetic resonance at 1.5 T seven days (5-10 days) after symptom onset (FU0), after 5 weeks (FU1), and after 6 months (FU2). Eighteen age- and sex-matched healthy subjects served as controls. Cardiovascular magnetic resonance included imaging of edema, hyperemia, necrosis, and fibrosis using semiquantitative T2-weighted spin echo, T2 mapping, and T1 mapping before and 3 and 10 minutes after gadobutrol administration. Extracellular volume for diffuse and late gadolinium enhancement for focal fibrosis were assessed. Compared with controls, patients had significantly higher global T2 times at FU0 (55.1 ms [53.3-57.2 ms] versus 50.2 ms [49.2-52.0 ms]; P<0.001) and at FU1 (52.0 ms [52.0-53.2 ms]; P=0.007), which normalized at FU2 (50.9 ms [49.6-53.3 ms]; P=0.323). Global native T1 times in patients were elevated acutely (1004 ms [988-1048 ms] versus 975 ms [957-1004 ms]; P=0.002) and remained elevated throughout the follow-up (FU1: 998 ms [990-1027 ms]; P=0.014; FU2: 1000 ms [972-1027 ms]; P=0.044). Global extracellular volume fraction was statistically not different between patients and controls (P=0.057). 77.8% (14/18) of patients had focal late gadolinium enhancement. T2 ratio was significantly elevated in patients with myocarditis at FU0 (2.2 [2.0-2.3] versus 1.6 [1.5-1.7]; P<0.001). The difference decreased during follow-up (FU1: 1.9 [1.7-1.9]; P=0.001 and FU2: 1.7 [1.7-1.8]; P=0.053). The diagnostic accuracy to discriminate between patients with acute myocarditis and healthy controls was 86% for T2>52 ms, 78% for native T1>981 ms, 74% for extracellular volume fraction >0.24, and 100% for T2 ratio >1.9. Conclusions: Although both T2 and T1 mapping reliably detected acute myocarditis, only T2 mapping discriminated between acute and healed stages, underlining the incremental value of T2 mapping.
  • Article
    Full-text available
    Background: Myocardial involvement in AAV patients might be silent, presenting with no or nonspecific symptoms, normal ECG, and preserved left-ventricular ejection fraction (LV-EF). Since up to 50% of deaths in these patients may be due to myocardial involvement, a reliable diagnostic tool is warranted. In contrast to LGE-CMR, which has its strengths in detecting focal inflammatory or fibrotic processes, recent mapping techniques are able to detect even subtle, diffuse inflammatory or fibrotic processes. Our study sought to investigate ANCA (antineutrophil cytoplasmic antibody) associated vasculitides (AAV) patients for myocardial involvement by a cardiovascular magnetic resonance (CMR) protocol, including late gadolinium enhancement (LGE) and mapping sequences. Methods: Thirty seven AAV patients were prospectively enrolled and underwent CMR imaging. Twenty healthy volunteers served as controls. Results: Mean LV-EF was 64%; LGE prevalence of the AAV patients was 43%. AAV patients had higher median native T1 (988 vs. 952 ms, p < 0.001), lower post-contrast T1 (488 vs. 524 ms, p = 0.03), expanded extracellular volume (ECV) (27.5 vs. 24.5%, p < 0.001), and higher T2 (53 vs. 49 ms, p < 0.001) compared to controls, with most parameters independent of the LGE status. Native T1 and T2 in AAV patients showed the highest prevalence of abnormally increased values beyond the 95% percentile of controls. Conclusion: AAV patients demonstrated increased T1, ECV, and T2 values, with native T1 and T2 showing the highest prevalence of values beyond the 95% percentile of normal. Since these findings seem to be independent of LGE, mapping techniques may provide complementary information to LGE-CMR in the assessment of myocardial involvement in patients with AAV.
  • Article
    Background—Cardiac sarcoidosis (CS) may manifest as arrhythmia or even sudden cardiac death. Because patients with CS often present with nonspeci c symptoms, normal electrocardiography, and preserved left ventricular ejection fraction, a reliable diagnostic tool for the work-up of CS is needed. Late gadolinium enhancement–cardiovascular magnetic resonance has proven diagnostic value in CS but has some limitations that may be overcome by adding newer cardiovascular magnetic resonance mapping techniques. The aim of our study was to evaluate a comprehensive cardiovascular magnetic resonance protocol, including late gadolinium enhancement and mapping sequences in sarcoid patients with no symptoms or unspeci c symptoms and preserved left ventricular ejection fraction. Methods and Results—Sixty-one sarcoid patients were prospectively enrolled and underwent comprehensive cardiovascular magnetic resonance imaging. Twenty-six healthy volunteers served as control group. Mean left ventricular ejection fraction was 65%; late gadolinium enhancement was only present in sarcoid patients (n=15). Sarcoid patients had a higher median native T1 (994 versus 960 ms; P<0.001), lower post contrast T1 (491 versus 526 ms; P=0.001), expanded extracellular volume (28 versus 25%; P=0.001), and higher T2 values (52 versus 49 ms; P<0.001) compared with controls. Among patients with values higher than the 95% percentile of healthy controls, most signi cant differences were observed for native T1 and T2 values. Most of these patients were late gadolinium enhancement negative. Conclusions—Patients with sarcoidosis demonstrate higher T1, extracellular volume, and T2 values compared with healthy controls, with most signi cant differences for native T1 and T2. While promising, the clinical signi cance of the newer mapping techniques with respect to early diagnosis and therapy of CS will have to be determined in future studies.
  • Article
    Full-text available
    Introduction: Cardiac involvement in systemic inflammatory diseases (SID) has a major impact on patients' morbidity and mortality, yet the pathways to its recognition and management remain poorly established. Areas covered: Overall clinical management in SID patients is primarily guided by systemic symptoms. Cardiovascular disease goes largely undetected, as it evolves through years of a protracted and subclinical course. Despite the increased awareness and insights into the mechanistic role of the inflammatory pathways, clinical management of cardiac involvement continues to rely on diagnostic means, which are frequently insensitive, inaccurate, invasive and rely on radiation exposure. Advanced tissue characterisation with cardiovascular magnetic resonance (CMR) offers an accurate, non-invasive and radiation-free diagnostic method with obvious advantages: owing to its versatile imaging readouts, it is able to inform on a range of cardiovascular pathophysiology, as well as support safe serial examinations, informing on the disease presence, progress and response to treatment. Expert commentary. We summarise the recent advances in non-invasive imaging, and bridge the novel insights into pathophysiology with future posibilities in diagnosis and manangement of SID patients. We propose an interdisciplinary framework to screening of cardiac involvement in SID using an indepth phenotyping of evolution of cardiovascular disease, to decipher the opportunities to improve patients' cardiac care.
  • Article
    Full-text available
    Background: Lupus myocarditis is likely more common than recognized clinically due to non-specific symptoms and lack of reliable non-invasive diagnostic tests. We investigated the role of native T1 and T2 in recognition of active myocardial inflammatory involvement in patients with systemic lupus erythematous (SLE). Methods: 76 patients with clinically suspected lupus myocarditis (14 males, age: 44±16years) underwent quantitative tissue characterization with native T1 and T2 mapping. Normotensive healthy subjects taking no medication served as controls (n=46). Follow-up CMR studies were performed in a total of 35 subjects of which 14 patients received intensified anti-inflammatory treatment, as guided by SLE disease activity. Results: Compared to controls SLE patients had higher inflammatory markers, LV mass, native T1 and T2 values, and reduced longitudinal strain (p<0.01). In patients with a positive troponin test (n=36; 46%), native T1 and T2 were significantly higher (p<0.01) with otherwise similar proportions of diffuse perimyocardial LGE (33%) and pericardial effusion (32%). Sixty-nine patients (83%) had an abnormal native T1, whereas 51 (71%) met diagnostic criteria for acute myocarditis. Follow-up CMRs revealed significantly greater reduction in native T1 and T2 values in patients with intensified anti-inflammatory treatment (p<0.001) with the greatest change observed within the first follow-up period and plateauing thereafter. Native T1 and T2 were significant predictors of treatment response. Conclusions: Native T1 and T2 mapping support recognition of lupus myocarditis and reflect the response to anti-inflammatory treatment. Native T1 and T2 mapping may support an effective, noninvasive, radiation- and gadolinium contrast-free screening method for lupus myocarditis.